531739 — Gennex Laboratories Income Statement
0.000.00%
- IN₹2.98bn
- IN₹2.81bn
- IN₹867.14m
- 38
- 43
- 15
- 19
Annual income statement for Gennex Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 556 | 596 | 612 | 656 | 867 |
Cost of Revenue | |||||
Gross Profit | 220 | 239 | 231 | 257 | 379 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 534 | 540 | 566 | 618 | 721 |
Operating Profit | 22.4 | 56.5 | 45.9 | 37.7 | 147 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 25.5 | 50.6 | 50.9 | 63.7 | 165 |
Provision for Income Taxes | |||||
Net Income After Taxes | 18.6 | 40.4 | 39.2 | 49.2 | 132 |
Net Income Before Extraordinary Items | |||||
Net Income | 18.6 | 40.4 | 39.2 | 49.2 | 132 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 18.6 | 40.4 | 39.2 | 49.2 | 132 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.134 | 0.327 | 0.296 | 0.337 | 0.705 |